Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 232.96 mg (equivalent: tapentadol, qty 200 mg) - tablet, modified release - excipient ingredients: iron oxide yellow; hypromellose; magnesium stearate; colloidal anhydrous silica; iron oxide red; lactose monohydrate; titanium dioxide; purified talc; microcrystalline cellulose; macrogol 6000; propylene glycol - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 174.72 mg (equivalent: tapentadol, qty 150 mg) - tablet, modified release - excipient ingredients: propylene glycol; magnesium stearate; iron oxide red; hypromellose; lactose monohydrate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; macrogol 6000; purified talc; iron oxide yellow - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 116.48 mg (equivalent: tapentadol, qty 100 mg) - tablet, modified release - excipient ingredients: magnesium stearate; microcrystalline cellulose; purified talc; titanium dioxide; macrogol 6000; hypromellose; colloidal anhydrous silica; propylene glycol; iron oxide yellow; lactose monohydrate - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 58.24 mg (equivalent: tapentadol, qty 50 mg) - tablet, modified release - excipient ingredients: titanium dioxide; lactose monohydrate; propylene glycol; hypromellose; purified talc; colloidal anhydrous silica; macrogol 6000; microcrystalline cellulose; magnesium stearate - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 116.48 mg (equivalent: tapentadol, qty 100 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; lactose monohydrate; iron oxide yellow; purified talc; povidone; titanium dioxide; iron oxide red; polyvinyl alcohol; microcrystalline cellulose; macrogol 3350; iron oxide black - palexia ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 87.36 mg (equivalent: tapentadol, qty 75 mg) - tablet, film coated - excipient ingredients: macrogol 3350; polyvinyl alcohol; iron oxide red; croscarmellose sodium; purified talc; lactose monohydrate; titanium dioxide; microcrystalline cellulose; povidone; magnesium stearate; iron oxide yellow - palexia ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 58.24 mg (equivalent: tapentadol, qty 50 mg) - tablet, film coated - excipient ingredients: purified talc; titanium dioxide; croscarmellose sodium; polyvinyl alcohol; lactose monohydrate; macrogol 3350; microcrystalline cellulose; povidone; magnesium stearate - palexia ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Južná Afrika - angličtina - South African Health Products Regulatory Authority (SAHPRA)

pharmaco distribution (pty) ltd - tablet - see ingredients - tablet diazepam 10 mg

Spojené arabské emiráty - angličtina - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

gulf drug llc spain - 25's blister - tablet - 5mg / tablet - central nervous system-hypnotics , anxiolytics

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - modafinil, quantity: 100 mg - tablet, uncoated - excipient ingredients: povidone; aluminium magnesium silicate; lactose monohydrate; purified talc; maize starch; croscarmellose sodium; magnesium stearate - modafinil is indicated:,? to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy;,? to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate;,? as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.